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Objective. Among rheumatoid arthritis (RA) pa-
tients, the intensity of pain may be out of proportion to
the severity of peripheral inflammation. This observa-
tion suggests that mechanisms of central nervous sys-
tem pain amplification, such as diminished conditioned
pain modulation (CPM), may play a role in enhancing
pain perception among some RA patients. This study
was undertaken to examine the level of CPM, pressure–
pain threshold, and pressure–pain tolerance among RA
patients compared to healthy controls.
Methods. Fifty-eight female RA patients and 54
age-matched female control subjects without chronic
pain underwent quantitative sensory testing (QST) to
assess CPM levels, pressure–pain thresholds, and
pressure–pain tolerance levels. CPM was induced using
a cold water bath, and the pain threshold (when patients
first felt pain) and pain tolerance (when pain was too
much to bear) were assessed with an algometer. Asso-
ciations between RA and each QST outcome were ana-
lyzed using linear regression. Sleep problems, mental
health, and inflammation were assessed as mediators of
the relationship between RA and QST outcomes.
Results. The median CPM level was 0.5 kg/cm2
(interquartile range [IQR] 0.1, 1.6) among RA pa-
tients, compared to a median of 1.5 kg/cm2 (IQR 0.1,
2.5) among controls (P  0.04). RA patients, compared
to controls, had a lower pain threshold and lower pain
tolerance at the wrists (each P < 0.05). In addition, RA
patients had greater problems with sleep, pain catastro-
phizing, depression, and anxiety (P < 0.0001 versus
controls). Results of mediation analyses suggested that
low CPM levels might be attributed, in part, to sleep
disturbance (P  0.04).
Conclusion. RA patients have impaired CPM
when compared to pain-free control subjects. Sleep
problems may mediate the association between RA and
attenuated CPM.
Pain is the most common and disabling symptom
of rheumatoid arthritis (RA). Although physicians often
assume that inflammation is the stimulus for pain, many
RA patients continue to have pain despite having ade-
quately suppressed inflammation (1). Studies of experi-
mental pain sensitivity have shown that the pressure–
pain threshold (i.e., the degree of pressure that first
elicits pain) is lower in RA patients than in healthy
controls (2,3). These thresholds are lower in the joints as
well as at sites outside the joints (4,5). The widespread
distribution of hyperalgesia suggests that the underlying
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mechanisms of pain originate from the central nervous
system (CNS), rather than at focal sites of peripheral
inflammation.
In animal models, one well-described CNS mech-
anism for modulating pain involves descending analgesic
pathways, being those that “descend” from the cerebral
cortex, hypothalamus, and brainstem to regulate peri-
pheral sensory input in the spinal cord (6). In response
to acutely painful stimuli, inhibitory pathways are acti-
vated, leading to a diffuse decrease in pain. In humans,
the effects of these pathways may be seen when the
perception of noxious stimuli, such as arthritis-related
pain, is momentarily attenuated after experiencing an-
other strong noxious stimulus, such as stubbing one’s
toe. In the experimental setting, this phenomenon has
been termed “loss of diffuse noxious inhibitory con-
trols,” or diminished conditioned pain modulation
(CPM) (7). The level of CPM can be measured with a
noninvasive test and is a sensitive measure of deficits in
central pain modulation in chronic, widespread pain
conditions (8).
In this study, we measured the level of CPM, the
pressure–pain threshold, and the pressure–pain toler-
ance (i.e., the degree of pressure that elicits unbearable
pain) among RA patients and age-matched healthy
control subjects. We also assessed the role of sleep
problems, mental health, and markers of inflammation
in mediating differences in CPM levels and pain sensi-
tivity. Variables were considered mediators if, when
added to the models, they partially or completely dimin-
ished the association between RA and the outcomes of
CPM, pressure–pain threshold, or pressure–pain toler-
ance. We hypothesized that RA patients would have
diminished CPM, a lower pressure–pain threshold, and a
lower pressure–pain tolerance when compared with
these same sensory measures in controls. We also hy-
pothesized that sleep problems and greater pain cata-
strophizing would mediate the differences in CPM lev-
els, pressure–pain thresholds, and pain tolerances
between RA patients and controls.
PATIENTS AND METHODS
Study population. This study compared quantitative
sensory testing (QST) measures, including measurements of
the CPM analgesic response, the pressure–pain threshold, and
the pressure–pain tolerance, between RA patients and age-
matched healthy control subjects. We recruited female RA
patients from the rheumatology clinics of an academic medical
center, and identified age-matched female control subjects
from a hospital-based registry for study volunteers and from
the surrounding community between April 2010 and July 2011.
Inclusion criteria included female sex and age 40 years. We
limited the study to women, because RA occurs predominantly
in women and because women are known to have lower pain
threshold and pain tolerance compared to men. Exclusion
criteria included the use of opioid pain medications and the
presence of cold-sensitive conditions. We required that the
diagnosis of RA in patients be confirmed by a board-certified
rheumatologist.
Control subjects were recruited to match RA patients
by age. Exclusion criteria for controls included 1) history of a
systemic inflammatory disease (e.g., RA, systemic lupus ery-
thematosus, seronegative spondylarthropathy), 2) history of a
chronic pain condition (e.g., osteoarthritis, fibromyalgia, mi-
graine headaches, irritable bowel syndrome), and 3) chronic
pain for any other reason. The Institutional Review Board of
Partners Healthcare approved the study. All participants pro-
vided their written informed consent.
Assessment of clinical variables. A board-certified
rheumatologist (VCL) performed a physical examination of
each subject, including determination of the tender and swol-
len joint counts. Blood samples were collected to assess the
serum levels of C-reactive protein (CRP), tumor necrosis factor 
(TNF), and interleukin-6 (IL-6). The extent of disease activ-
ity in RA patients was determined using the Disease Activity
Score in 28 joints (DAS28), calculated from the tender joint
count, swollen joint count, and CRP level (9). Participants with
a DAS28 2.6 are considered in remission, whereas a DAS28
between 2.6 and 3.2 is considered low disease activity, and a
DAS28 5.1 indicates high disease activity. In addition, a list
of all current medications was obtained from each subject.
Clinical pain severity was assessed using the current
pain numeric rating scale (0–10) on the Brief Pain Inventory–
Short Form, a 9-question survey regarding the sensory and
reactive aspects of clinical pain. The subjects’ mental health
was measured using the Hospital Anxiety and Depression
Scale (HADS), a validated 14-item questionnaire that assesses
depression and anxiety in physically ill patients (10). A score
8 on the anxiety or depression subscales suggests difficulties
with anxiety or depression. We quantified sleep disturbances
using the Medical Outcomes Study (MOS) Sleep Scale (Sleep
Problems Index II), a validated 12-item questionnaire that
assesses sleep problems in chronically ill patients (11). A score
35 indicates sleep problems. The extent of pain catastro-
phizing was measured using the Pain Catastrophizing Scale, a
validated 13-item scale that assesses a set of negative cognitive
and emotional processes, including helplessness, pessimism,
rumination, and magnification of symptoms (12). Scores on
this scale range 0–52 (higher scores indicate greater catastro-
phizing). All data were double-entered by 2 individuals, and
entries were checked against each other for accuracy.
Quantitative sensory testing. QST techniques con-
sisted of measurement of the pressure–pain threshold and
pressure–pain tolerance levels, as well as a paradigm to test
CPM. One rheumatologist (YCL), trained in QST, performed
all testing. She explained the procedures using standard scripts
and was blinded to each subject’s case or control status. To
ensure that a subject’s RA status, as would be evident on
physical examination, was masked, each participant wore large
cotton gloves to cover the hands and wrists, the most common
sites of RA-related inflammation and structural damage.
All pain threshold and pain tolerance tests were per-
formed twice on the same day, with 2–5 minutes separating
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each test. The first test was designated a trial run, to accustom
participants to the testing procedures. The second test was
designated the test run, from which all data were obtained.
Tests were performed on the same day to minimize heterogen-
eity caused by daily changes in environment, disease activity,
and mental status. Our previous studies have indicated that
pressure–pain thresholds and tolerances are highly reproduc-
ible when testing is done on the same day (13).
Pressure–pain threshold and pressure–pain tolerance
testing was performed on the joints (at the dorsal wrists, on the
ulnar side of the extensor pollicis longus tendon, and at the
knees, immediately proximal to the patella), at sites close to
the joints (the thumbnails), and at sites distant from the joints
(superior trapezius muscles), using a Wagner Instruments FPK
20 algometer. This instrument has an accuracy of 2 gradua-
tions for capacities up to 2,500 grams, and 1 graduation for
capacities larger than 2,500 grams. It provides reproducible
measurements of pain threshold and pain tolerance among RA
patients, with intraclass correlations ranging from 0.75 to 0.92
(13).
Pressure was increased at a rate of 1 kg/second to a
maximum of 11 kg. The pressure–pain threshold was defined
as the degree of pressure when the participants first felt pain.
The pressure–pain tolerance level was defined as the degree of
pressure when the participants wanted to stop testing due to a
sensation of “too much pain.” The order of testing was as
follows: 1) the thumbnails, 2) the wrists, 3) the trapezius
muscles, and 4) the knees. The order was standardized to
ensure uniformity of study measurements. The order was
chosen such that areas outside the joints were interspersed
with joint-specific areas, minimizing the risk of systematic bias
toward the joints, relative to nonjoint sites. All assessments
were performed bilaterally.
The CPM paradigm was performed using a condition-
ing stimulus (a relatively tonic noxious stimulus that leads to
activation of CPM) and a test stimulus (a briefly painful
stimulus used to evaluate the analgesic response to the condi-
tioning stimulus) (14–16). The conditioning stimulus was im-
mersion of the right hand in a cold water bath at 6°C, and the
test stimulus was application of pressure to the left superior
portion of the trapezius muscle. Participants were instructed to
put their hand in the water bath for 30 seconds. The pressure–
pain threshold was assessed immediately before immersion
and 20 seconds after immersion, while each participant’s hand
remained in the cold water. The magnitude of CPM was
defined as the change in pressure–pain threshold from baseline
to 20 seconds after cold water immersion. Positive scores are
indicative of a greater analgesic response to the cold pressor
test (i.e., higher CPM levels).
Power calculation. The standard deviation of CPM
among RA patients and healthy control subjects was estimated
from a small study of 21 RA patients and 21 healthy controls
(4). With an alpha level of 0.05 and a standard deviation of
1.5 kg/cm2, a sample size of 50 RA patients and 50 controls
would provide 90% power to detect a difference in the CPM of
1.0 kg/cm2. Additional participants were enrolled to ensure
adequate power, in case the data were not obtainable from all
participants. This precaution was undertaken to account for
participants with pressure–pain thresholds exceeding the up-
per limit of detection (11 kg/cm2) at baseline, because further
increases in the pressure–pain threshold would not be detect-
able.
Statistical analysis. All statistical analyses were per-
formed using the SAS statistical software package (version
9.2). Results for continuous variables were expressed as the
median and interquartile range (IQR). Fisher’s exact test,
Wilcoxon’s rank sum test, and simple linear regression models
were used to compare clinical variables between RA patients
and controls, as appropriate. Unadjusted associations between
the RA diagnosis and QST outcomes were assessed using
simple linear regression. We analyzed adjusted associations
between RA and QST outcomes using multivariable linear
regression, in models in which, first, RA was included and,
subsequently, covariates (scores on the MOS Sleep Problems
Index II, HADS depression scale, HADS anxiety scale, and
Pain Catastrophizing Scale, the swollen joint count, and serum
levels of CRP, TNF, and IL-6) were added. We also exam-
ined first-order interactions between the presence of RA and
each covariate.
The strength of each association was determined using
beta regression coefficients and P values for the Type III sum
of squares estimates, which are not affected by the order of
variable entry. The beta coefficient represents the difference in
outcome between RA cases and controls. The threshold for
significance was set as a two-tailed P value of less than or equal
to 0.05.
If the beta coefficient for RA was found to be de-
creased by 20% in adjusted analyses, as compared to unad-
justed analyses, we conducted mediation analyses according to
the Baron and Kenny criteria (17). Specifically, we used simple
and multivariable linear regression models to assess whether 1)
the independent variable was significantly associated with the
dependent variable, 2) the independent variable was signifi-
cantly associated with the proposed mediator, and 3) the
proposed mediator was significantly associated with the depen-
dent variable, when adjusted for the independent variable. To
confirm these results, we also assessed the proposed mediators
via Sobel’s test and a nonparametric bootstrapping approach,
utilizing 5,000 bootstrap samples (18).
To explore the possibility that use of medications for
RA may have contributed to differences in QST results
between RA patients and controls, we used simple linear
regression to assess the association between medications (non-
steroidal antiinflammatory drugs [NSAIDs], corticosteroids,
nonbiologic disease-modifying antirheumatic drugs
[DMARDs], and biologic DMARDs) and the CPM level,
pressure–pain threshold, and pressure-pain tolerance level
among all RA patients.
RESULTS
Characteristics of the study subjects. RA pa-
tients (n  58) did not differ from controls (n  54) in
age, race, smoking status, or alcohol use (Table 1). No
participants had a history of peripheral neuropathy. Six
participants had diabetes; these participants were evenly
distributed among the case and control groups. Eighteen
patients were taking serotonin reuptake inhibitors. Five
patients were taking medications for neuroleptic disor-
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ders, and 1 patient was taking a tricyclic antidepressant.
The percentage of subjects taking these medications did
not differ significantly between RA patients and controls.
Compared to healthy control subjects, RA pa-
tients had significantly higher serum levels of CRP (P 
0.0005), TNF (P  0.01), and IL-6 (P  0.0001). RA
patients were also significantly more likely to have
problems with anxiety, depression, sleep, and pain cata-
strophizing compared to controls (P  0.0001). RA
patients were more likely to be taking NSAIDs, cortico-
steroids, nonbiologic DMARDs, and biologic DMARDs
(P  0.0001 versus controls).
Clinical pain severity scores were significantly
higher among RA patients as compared to controls (P
0.0001). Spearman’s correlation coefficients for associa-
tions of clinical pain scores with QST measures of pain
varied from0.12 for the pressure–pain threshold at the
left trapezius, to 0.33 for pressure–pain tolerance at
the right wrist. The Spearman’s correlation was 0.17
for the association between clinical pain intensity and
the level of CPM.
Among the RA patients, the median number of
swollen joints was 0.5 (IQR 0.0–3.0) (Table 1). Eight of
116 wrists (6.9%) and 12 of 116 knees (10.3%) were
swollen. Compared to joints that were not swollen, joints
that were swollen had lower pain thresholds, although
this was only statistically significant for measurements at
the right wrist (P  0.05).
Unadjusted associations between RA and QST
measures. The median CPM level was lower among RA
patients (median 0.5 kg/cm2, IQR 0.1, 1.6) compared
to control subjects without chronic pain conditions (me-
dian 1.5 kg/cm2, IQR 0.1, 2.5; P  0.04) (Figure 1).
Figure 1. Distribution of conditioned pain modulation levels among
rheumatoid arthritis patients and healthy control subjects.
Table 1. Clinical characteristics of the rheumatoid arthritis (RA) patients and healthy control subjects*
Characteristic RA patients (n  58) Controls (n  54) P
Demographic
Age, mean  SD years 60.9 9.7 62.5  9.3 0.34
White 53 (91.4) 44 (81.5) 0.17
Current smoker 4 (6.9) 4 (7.4) 1.00
Alcohol use 12 (20.7) 10 (18.5) 0.82
Postmenopausal 48 (82.8) 44 (81.5) 0.80
Measures of inflammation/pain, median (IQR)
Tender joint count 3.0 (1.0, 5.0) 0.0 (0.0, 0.0) 0.0001
Swollen joint count 0.5 (0.0, 3.0) 0.0 (0.0, 0.0) 0.0001
C-reactive protein, mg/liter 1.4 (0.6, 4.1) 0.6 (0.3, 1.4) 0.0005
IL-6, pg/ml 2.8 (1.6, 6.4) 1.4 (1.2, 2.3) 0.0001
TNF, pg/ml 1.9 (1.0, 5.0) 1.3 (1.0, 1.8) 0.01
DAS28 2.7 (2.5, 3.3) 1.4 (1.3, 1.7) 0.0001
BPI current pain severity score 2.0 (1.0, 4.0) 0.0 (0.0, 0.0) 0.0001
Sleep/mental health measures, median (IQR)
HADS anxiety score 5.5 (4.0, 9.0) 2.0 (1.0, 4.0) 0.0001
HADS depression score 3.0 (1.0, 6.0) 1.0 (0.0, 3.0) 0.0001
MOS Sleep Problems Index II score 30.6 (20.6, 48.9) 13.3 (5.6, 20.6) 0.0001
Pain Catastrophizing Scale score 11.0 (4.0, 21.0) 0.0 (0.0, 3.0) 0.0001
Medication use
NSAIDs 22 (37.9) 1 (1.9) 0.0001
Corticosteroids 16 (27.6) 0 (0.0) 0.0001
Nonbiologic DMARDs 38 (65.5) 0 (0.0) 0.0001
Biologic DMARDs 27 (46.6) 0 (0.0) 0.0001
* Except where indicated otherwise, values are the number (%) of subjects. IQR  interquartile range;
IL-6  interleukin-6; TNF  tumor necrosis factor ; DAS28  Disease Activity Score in 28 joints
(measured from the tender joint count, swollen joint count, and C-reactive protein level); BPI  Brief
Pain Inventory; HADS  Hospital Anxiety and Depression Scale; MOS  Medical Outcomes Study;
NSAIDs  nonsteroidal antiinflammatory drugs; DMARDs  disease-modifying antirheumatic drugs.
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When compared to controls, RA patients had signifi-
cantly lower pressure–pain thresholds at the wrists and
the right knee (P  0.05), and had lower pressure–pain
tolerance (P  0.03) at the wrists and knees bilaterally
(Table 2). The pain thresholds and pain tolerance levels
at the thumbs and trapezius muscles were also lower
among RA patients compared to controls, but these
differences were not statistically significant (Table 2).
Adjusted associations between RA and CPM.
The beta coefficient for the association between RA and
level of CPM decreased by 20% when the MOS sleep
problems score was added to linear regression models
assessing the association between RA and CPM, sug-
gesting that sleep problems may either mediate or
confound this association (Table 2). In analyses strati-
fied by clinical pain intensity scores, similar decrements
in the beta coefficient for the association between RA
and level of CPM were noted.
No significant decreases in the beta coefficients
for RA were noted when the pain catastrophizing score,
HADS anxiety score, HADS depression score, swollen
joint count, serum CRP level, serum TNF level, or
serum IL-6 level was added individually as a covariate to
the models. No significant changes in the beta coeffi-
cients for RA were noted when diabetes mellitus, use of
tricyclic antidepressant drugs, use of serotonin reuptake
inhibitors, or use of medications for neuroleptic disor-
ders was added individually to the models.
Adjusted associations between RA and pain
threshold and pain tolerance. The beta coefficients for
the association between RA and pain thresholds and
pain tolerance levels at the wrists and knees decreased
by20% when the pain catastrophizing score was added
to the models, suggesting that the extent of pain cata-
strophizing may either mediate or confound these rela-
tionships (Table 2). The beta coefficient for the associ-
ation between RA and the pressure–pain threshold at
the left wrist increased by 20% when the MOS sleep
problems score was added to the model (Table 2), and
the beta coefficient for the association between RA and
Table 2. Measures of central pain, pressure–pain threshold, and pressure–pain tolerance in rheumatoid arthritis (RA) patients (n 58) compared
to healthy controls (n  54)*
Median (IQR) kg/cm2 Model 1† Model 2† Model 3†
QST outcome RA patients Controls  P  P  P
Central pain, CPM 0.5 (0.1, 1.6) 1.5 (0.1, 2.5) 0.59 0.04 0.19‡ 0.57 0.60 0.09
Pressure–pain threshold
Wrist
Left 6.1 (4.8, 8.5) 7.7 (5.7, 11.0) 0.99 0.05 1.21 0.04 0.40‡ 0.49
Right 6.8 (4.8, 8.8) 8.1 (6.0, 10.3) 1.06 0.03 0.99 0.08 0.54‡ 0.32
Knee
Left 8.4 (6.0, 11.0) 9.2 (7.5, 11.0) 0.76 0.10 0.90 0.10 0.05‡ 0.93
Right 7.5 (5.9, 11.0) 9.4 (7.3, 11.0) 1.17 0.01 1.30 0.02 0.67‡ 0.19
Thumb
Left 6.4 (4.4, 8.3) 6.9 (5.7, 11.0) 0.57 0.25 — — — —
Right 6.7 (5.0, 9.8) 8.1 (5.7, 9.8) 0.53 0.31 — — — —
Trapezius
Left 5.5 (3.8, 7.8) 6.2 (4.1, 8.1) 0.37 0.45 — — — —
Right 5.2 (3.8, 7.9) 6.4 (4.2, 9.3) 0.61 0.23 — — — —
Pressure–pain tolerance
Wrist
Left 8.0 (6.2, 11.0) 10.4 (7.3, 11.0) 1.04 0.02 1.23 0.01 0.79‡ 0.11
Right 8.8 (6.3, 11.0) 11.0 (8.1, 11.0) 1.28 0.002 1.31 0.007 0.89‡ 0.05
Knee
Left 9.8 (7.8, 11.0) 11.0 (8.9, 11.0) 0.90 0.03 0.89 0.06 0.40‡ 0.35
Right 9.0 (7.4, 11.0) 11.0 (9.8, 11.0) 1.28 0.001 1.39 0.004 0.86‡ 0.20
Thumb
Left 8.5 (6.2, 11.0) 9.0 (7.1, 11.0) 0.55 0.23 — — — —
Right 9.8 (7.2, 11.0) 11.0 (8.5, 11.0) 0.60 0.17 — — — —
Trapezius
Left 7.1 (4.8, 9.5) 8.2 (5.2, 10.5) 0.51 0.32 — — — —
Right 7.0 (4.8, 9.0) 8.8 (5.2, 11.0) 0.82 0.12 — — — —
* QST  quantitative sensory testing; IQR  interquartile range; CPM  conditioned pain modulation.
† Values are the beta coefficient and P value for the association between RA and each outcome, as assessed in model 1 (unadjusted), model 2
(adjusted for sleep problems), and model 3 (adjusted for pain catastrophizing score).
‡ The beta coefficient is decreased 20% from the unadjusted value in model 1. Because mediation can occur only when the original association
between the independent and dependent variable is significant, the beta coefficients and P values are provided only for models in which the P value
for the original association between RA and the outcome was 0.10.
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the pressure–pain threshold at the left knee increased by
20% when the HADS anxiety score was added to the
model. No changes in the beta coefficients for RA were
noted when the HADS depression score, swollen joint
count, serum CRP level, serum TNF level, or serum
IL-6 level was added individually to the models assessing
the association between RA and pain threshold and pain
tolerance at the wrists and knees.
Associations in mediation analyses. Mediation
analyses were conducted to identify mediators of the
association between RA and CPM levels, and between
RA and pressure–pain thresholds and pressure–pain
tolerance levels at the wrists and knees. All 3 Baron and
Kenny criteria were satisfied when the MOS sleep
problems score was assessed as a mediator of the
association between RA and the level of CPM: 1) RA
was significantly associated with the level of CPM (P 
0.04); 2) RA was significantly associated with the MOS
Sleep Problems Index II score (P  0.0001); and 3) the
MOS Sleep Problems Index II score was significantly
associated with the level of CPM after adjustment for
the presence of RA (P  0.03) (Table 3 and Figures 2A
and B). According to the results from Sobel’s test, the
association between RA and the level of CPM was
significantly reduced by inclusion of the MOS Sleep
Problems Index II score in the model (  0.59 in
unadjusted analyses versus   0.19 after adjustment
for sleep problems; P  0.04) (Figures 2A and B).
Moreover, based on analyses utilizing the bootstrapping
approach, the 95% confidence interval for the indirect
effect of RA on the CPM level, mediated by sleep
problems, did not overlap with zero (Table 3).
Figure 2. A, Unadjusted association between rheumatoid arthritis and
conditioned pain modulation (Baron and Kenny criterion #1). B,
Mediation analyses showing 1) the association between rheumatoid
arthritis and conditioned pain modulation, adjusted for sleep prob-
lems, and 2) the associations between rheumatoid arthritis and sleep
problems (Baron and Kenny criterion #2) and sleep problems and
conditioned pain modulation, adjusted for rheumatoid arthritis (Baron
and Kenny criterion #3).
Table 3. Analyses of sleep disturbances as a mediator of the association between rheumatoid arthritis (RA) and each
quantitative sensory testing (QST) outcome, according to the Baron and Kenny criteria, Sobel’s test, and bootstrapping
analyses*
QST outcome
Baron and Kenny criteria
Sobel’s
test
Bootstrapping analysis
of the indirect effect
of RA on QST
outcome, through
sleep problems
Association
between RA
and QST
outcome
Association
between RA
and sleep
problems
Association between
sleep problems and
QST outcome,
adjusted for RA
Central pain, CPM 0.04 0.0001 0.03 0.04 0.74, 0.04
Pressure–pain threshold
Wrist
Left 0.05 0.0001 0.49 0.49 0.76, 1.22
Right 0.03 0.0001 0.83 0.83 1.13, 0.83
Knee
Left 0.10 0.0001 0.63 0.63 0.67, 0.92
Right 0.01 0.0001 0.65 0.66 0.72, 1.02
Pressure–pain tolerance
Wrist
Left 0.02 0.0001 0.41 0.42 0.58, 1.04
Right 0.002 0.0001 0.89 0.89 0.79, 0.77
Knee
Left 0.03 0.0001 0.98 0.98 0.78, 0.65
Right 0.001 0.0001 0.67 0.67 0.64, 0.88
* Each row represents a separate model. For associations tested according to the Baron and Kenny criteria and Sobel’s
test, the values are P values, while values in bootstrapping analyses are the 95% confidence interval of the indirect effect.
CPM  conditioned pain modulation.
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The Baron and Kenny criteria were not satisfied
when pain catastrophizing scores were analyzed as a
mediator of the relationship between RA and pressure–
pain thresholds and pressure–pain tolerance levels at the
wrists and knees. Although we found that RA was
significantly associated with the pain threshold and the
pain tolerance level, and that RA was significantly
associated with the pain catastrophizing score, no signif-
icant association between the pain catastrophizing score
and either the pain threshold or pain tolerance level was
seen after adjustment for the presence of RA. Further-
more, neither the results of Sobel’s test nor findings
from the bootstrapping approach indicated that pain
catastrophizing was a mediator of the association be-
tween RA and pain threshold and pain tolerance at the
wrists and knees.
Interactions. Analyses to assess the effects of
interaction between RA diagnosis and the MOS Sleep
Problems Index II score and between RA diagnosis and
the pain catastrophizing score on QST outcomes showed
that neither of these interactions was significantly asso-
ciated with the level of CPM. However, the interaction
between RA diagnosis and the MOS Sleep Problems
Index II score was significantly associated with the
pressure–pain threshold at the left thumb (P  0.03),
and the interaction between RA diagnosis and the pain
catastrophizing score was significantly associated with
the pressure–pain threshold at the right knee (P 0.04).
Associations with medication use. Among RA
patients, use of nonbiologic DMARDs was significantly
associated with higher pain thresholds (P  0.05) at the
left thumb and right trapezius, and also significantly
associated with higher pain tolerance (P  0.05) at the
thumbs and trapezius muscles bilaterally. Use of nonbio-
logic DMARDs was not significantly associated with the
level of CPM or the pain threshold and pain tolerance
level at the wrists and knees. Use of NSAIDs, cortico-
steroids, and biologic DMARDs was not associated with
the level of CPM or the pain threshold and pain
tolerance level at any site.
DISCUSSION
In this study, we examined QST measures of
central pain among RA patients compared to healthy
controls. Our results showed that RA patients have
attenuated CPM compared to controls, suggesting that
descending analgesic mechanisms are impaired. This
observation is consistent with studies comparing the
level of CPM between patients in other chronic pain
populations (e.g., fibromyalgia and osteoarthritis) and
healthy controls (19,20). Functional neuroimaging stud-
ies have also identified changes in neural activity in the
periaqueductal grey, anterior cingulate cortex, and other
pain-responsive areas of the brain in response to exper-
imental induction of CPM (21,22). Taken together,
these studies suggest that a set of common central
mechanisms, including impaired CPM, may contribute
to numerous chronic pain states. The association be-
tween these measures and clinical pain intensity, how-
ever, has varied, with some studies showing a significant
inverse correlation between the CPM level and clinical
pain measures (23), and other studies showing no asso-
ciation (24).
Only one other study has examined the role of
CPM in RA. In contrast to our study, Leffler et al
reported no statistically significant differences in the
level of CPM between 21 RA patients and 21 healthy
controls (4). The differences in results may reflect
differences in statistical power, as the present study had
over twice as many subjects. Similar to our study, the
mean level of CPM in the Leffler et al study was lower
(but not significantly [P  0.05]) among RA patients
compared to pain-free controls.
Pressure–pain thresholds and pressure–pain tol-
erances were also lower among RA patients than among
controls in our study. However, in contrast to previous
studies (4,5), these differences were only significant in
the joints, but not at sites outside the joints. The stronger
association with pain threshold and pain tolerance in the
joints may be due, in part, to peripheral sensitization
resulting from inflammation of the joints. In animal
models, it is well established that peripheral inflamma-
tion can sensitize peripheral nerve endings, leading to
lower pain thresholds (25). In a previous study, we also
demonstrated that the serum CRP level was significantly
associated with the pain threshold at the wrist, but not at
sites outside the joints (26). Taken together, these
results provide further support for the idea that inflam-
mation is related to peripheral sensitization in patients
with RA.
Interaction analyses did not suggest a differential
association of either sleep problems or pain catastroph-
izing with the level of CPM, depending on the presence
of RA. Although the P values for the association be-
tween 1) RA diagnosis by MOS Sleep Problems Index II
score and pressure–pain threshold at the left thumb, and
2) RA diagnosis by pain catastrophizing score and
pressure–pain threshold at the right knee were both less
than 0.05, the clinical significance of these associations is
unclear, since these interactions were analyzed ad hoc,
and interactions at other sites were not significant.
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Statistical significance may have been a by-product of
multiple comparisons. Future analyses are needed to
replicate these results.
The association between RA and CPM level was
greatly attenuated when sleep problems were included
as a covariate in the multivariable model. This observa-
tion suggests that sleep problems may confound or
mediate the relationship between RA and CPM. Results
of mediation analyses, including fulfillment of the Baron
and Kenny criteria as well as results from Sobel’s test
and the confidence intervals obtained from the nonpara-
metric bootstrapping approach, all indicated that the
indirect effect of RA on the level of CPM through sleep
problems (i.e., the effect that occurred due to sleep
problems, rather than the direct effect of RA itself on
the CPM) was statistically significant.
In the proposed mediation pathway (Figure 2B),
RA is associated with a lower CPM level because 1) RA
patients have more sleep problems, and 2) sleep prob-
lems lead to impaired CPM. Sleep disturbances are
more common among RA patients than among the
general population (27), occurring in 50–70% of RA
patients (28). Although no studies have examined the
association between sleep fragmentation and CPM lev-
els among RA patients, studies of patients with tem-
poromandibular joint disorder suggest that sleep distur-
bances are cross-sectionally associated with
experimental pain sensitivity (29) and prospectively as-
sociated with clinical pain severity (30). In addition,
studies of healthy adults and adults with temporoman-
dibular joint disorder indicate that sleep fragmentation
is significantly associated with decreases in the CPM
level (24,31).
The relationship between sleep problems and
pain, however, is complex. While sleep problems appear
to mediate the association between RA and the level of
CPM, other variables, such as pain itself, may factor into
this relationship. Given that control subjects were ex-
cluded if they reported the presence of chronic pain,
cases and controls differed in the pain experience. A
study of 106 RA patients showed that pain significantly
contributes to sleep problems (32). Thus, the appear-
ance of mediation by sleep may actually be the result of
mediation by chronic pain, as both may be on the same
causal pathway. However, because pain was an exclusion
criterion for the controls, it was not possible to assess
pain as a confounder or mediator in these analyses.
Analyses stratified by clinical pain intensity in the RA
group did not suggest differences in the mediating effect
of sleep problems on the CPM level.
While sleep problems altered the strength of
association between RA and CPM, pain catastrophizing
diminished the association between RA and pain thresh-
old and pain tolerance at the wrists and knees. However,
mediation analyses did not support the role of pain
catastrophizing as a mediator of the relationship be-
tween RA and pain threshold or pain tolerance. The
associations between pain catastrophizing and pain
threshold and pain tolerance were not significant after
adjusting for the presence of RA, suggesting that pain
catastrophizing may be collinear with other factors as-
sociated with the RA diagnosis. Alternatively, the lack of
significance in these tests may be due to the small
sample size, limited distribution of pain catastrophizing
scores, and/or asymmetric distributions of the indirect
effect of RA on pain threshold and pain tolerance.
Although no studies have examined the associa-
tion between the extent of pain catastrophizing and
either the CPM level or pain threshold and pain toler-
ance levels in RA, a greater pain catastrophizing score
has been associated with high self-reported pain severity
among RA patients (33,34). Pain catastrophizing scores
are also inversely associated with pressure–pain thresh-
olds and pressure–pain tolerance levels in patients with
fibromyalgia and patients with osteoarthritis (35–38).
Future studies are needed to elucidate the role of pain
catastrophizing in the processing and ultimate expres-
sion of pain in RA.
This study has several limitations. First, the cross-
sectional design makes it impossible to assess causality.
Because the distinction between confounding and medi-
ation is based on a presumed causal relationship among
variables, this study cannot distinguish between con-
founding and mediation, even though the results of
mediation analyses were statistically significant (39,40).
In studies of other populations (e.g., patients after knee
arthroscopy), a causal relationship between sleep prob-
lems and pain has been suggested based on improve-
ments in pain after treatment of sleep disturbances
(41,42). In future studies, it will be important to assess
whether interventions that improve sleep in RA patients
could “normalize” CPM measures. Larger, longitudinal
studies examining the interplay between pain, mental
health, sleep problems, CPM, pain threshold, and pain
tolerance are also needed to understand how these
factors interact in shaping CNS processing of pain-
related information in RA.
Other potential limitations include confounding
by medications. Although we excluded individuals taking
opioids, participants could continue to take other med-
ications that may alter the CPM level, pain threshold,
and pain tolerance level. Use of NSAIDs, cortico-
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steroids, and DMARDs was observed almost exclusively
in RA patients, and thus may be the cause of differences
in the CPM level, pain threshold, and pain tolerance
between RA patients and controls. However, among RA
patients, none of these medications, except nonbiologic
DMARDs, was significantly associated with the CPM
level, pain threshold, or pain tolerance. Nonbiologic
DMARDs were associated with a high pressure–pain
threshold and high pressure–pain tolerance level at the
thumb and trapezius, but these associations were in the
opposite direction of what would be expected if nonbio-
logic DMARDs were a proxy for RA diagnosis. Future
studies are needed to examine the effect of medications
on central pain mechanisms.
Finally, it is possible that the use of large cotton
gloves to blind the assessor to RA/control status altered
the pain-testing results. In a pilot study of 8 healthy
women, the median difference in pain threshold be-
tween participants wearing gloves and those not wearing
gloves was 0.30 kg/cm2, indicating that gloves do not
significantly alter pain thresholds in healthy controls. In
a separate study of 8 women with RA, the median
difference in pain threshold was 0.74 kg/cm2. These
results suggest that, if anything, gloves increase pain
thresholds in RA patients compared to controls, biasing
results toward the null. Thus, the use of gloves, which
was necessary for blinding, may have decreased our
power, but there was no evidence that this confounded
the analysis of group differences in CPM (which did not
involve a gloved site) or produced spurious findings.
In conclusion, RA patients had lower CPM levels
and lower pressure–pain threshold and pressure–pain
tolerance at the joints when compared to pain-free
controls. The association between RA and diminished
CPM may be mediated by sleep problems. These results
highlight the importance of considering central pain
mechanisms when evaluating and addressing pain in
chronic inflammatory diseases such as RA. Future stud-
ies are needed to examine whether improving sleep and
managing pain catastrophizing may prevent or reverse
the development of abnormal pain mechanisms and,
ultimately, improve pain control in RA. Functional
neuroimaging studies may also be illuminating, as sev-
eral recent functional magnetic resonance imaging stud-
ies (22,43) have investigated the neural underpinnings of
CPM.
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